RT Journal Article
SR Electronic
T1 Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a randomised, double-blinded, phase 2/3, placebo-controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.28.21255834
DO 10.1101/2021.04.28.21255834
A1 Fragoso-Saavedra, Sergio
A1 Núñez, Isaac
A1 Audelo-Cruz, Belem M.
A1 Arias-Martínez, Sarahi
A1 Manzur-Sandoval, Daniel
A1 Quintero-Villegas, Alejandro
A1 Benjamín García-González, H.
A1 Carbajal-Morelos, Sergio L.
A1 de León-Rosales, Sergio Ponce
A1 Gotés-Palazuelos, José
A1 Maza-Larrea, José A.
A1 Caro-Vega, Yanink
A1 Batina, Isabella
A1 Islas-Weinstein, León
A1 Iruegas-Nunez, David A.
A1 Calva, Juan J.
A1 Belaunzarán-Zamudio, Pablo F.
A1 Sierra-Madero, Juan
A1 Crispín, José C.
A1 Valdés-Ferrer, Sergio I.
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.04.28.21255834.abstract
AB Background Hospitalised patients with severe COVID-19 have an increased risk of developing acute respiratory distress syndrome (ARDS) and death from severe systemic inflammatory response. Acetylcholine modulates the acute inflammatory response through a neuro-immune mechanism known as the inflammatory reflex. Pyridostigmine, an acetylcholine-esterase inhibitor, increases the half-life of endogenous ACh, reducing lung and systemic inflammation in murine sepsis. This trial aimed to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19.Methods We performed a parallel-group, multicentre, double-blinded, placebo-controlled, randomised clinical trial in two COVID-19-designated hospitals in Mexico City, Mexico. Adult (≥ 18-year-old), hospitalised patients with confirmed SARS-CoV-2 infection based on a positive RT-PCR test in a respiratory specimen, a computed tomography compatible with pneumonia, as well as requiring supplementary oxygen were included. Patients were randomly assigned (1:1) to receive oral pyridostigmine (60 mg per day) or placebo for a maximum of 14 days. The intention-to-treat analysis included all the patients who underwent randomisation. The primary endpoint was the composite outcome of initiation of IMV and 28-day all-cause mortality. The trial is registered in ClinicalTrials.gov, NCT04343963.Findings Between May 5, 2020, and Jan 29, 2021,188 participants were randomly assigned to placebo (n=94) or pyridostigmine (n=94). The composite outcome occurred in 22 (23·4%) vs. 11 (11·7%) participants, respectively (hazard ratio 0·46, 95% CI 0·22-0·96, p=0·03). The most frequent adverse event was diarrhoea (5 [5·3%] in the pyridostigmine group vs 3 [3·2%] in the placebo group). Most of the adverse events were mild to moderate, with no serious adverse events related to pyridostigmine.Interpretation Our data indicates that the addition of pyridostigmine to standard treatment reduces significantly the fatality rate among patients hospitalized for severe COVID-19.Funding Consejo Nacional de Ciencia y Tecnología, México.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04343963Clinical Protocols https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05485-7 Funding StatementFunded by Consejo Nacional de Ciencia y Tecnología, México (COVID-19 Fund [F0005-2020-01]; grant 311790), to SIV-F].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comité de Investigación en Humanos y Comité de Ética en Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data will be made available upon request to the corresponding author